Gastrointest Endosc. 2011 Jan;73(1):149-53. doi: 10.1016/j.gie.2010.09.031.
In unresectable malignant bile duct obstruction in a patient with a life expectancy longer than 3 months, the use of self-expandable metal stents (SEMSs) is the standard technique to ensure continued biliary drainage. As many as 50% of patients with SEMSs will present with stent occlusion within 6 months. Changes to stent design and composition and concomitant therapy have failed to improve stent patency; therefore, alternative techniques to safely prolong stent patency are required.
To demonstrate the safety of endobiliary bipolar radiofrequency ablation (RFA) in patients with malignant biliary obstruction and to report the 90-day biliary patency of this novel procedure.
Open-label pilot study.
Single tertiary care unit.
A total of 22 patients with unresectable malignant bile duct obstruction.
Bipolar RFA within the bile duct.
Immediate and 30-day complications and 90-day stent patency.
A total of 22 patients (16 pancreatic, 6 cholangiocarcinoma) were recruited between January 2009 and April 2010. Deployment of an RFA catheter was successful in 21 patients. SEMS placement was achieved in all cases of successful RFA catheter deployment. One patient failed to demonstrate successful biliary decompression after SEMS placement and died within 90 days. All other patients maintained stent patency at 30 days. One patient had asymptomatic biochemical pancreatitis, 2 patients required percutaneous gallbladder drainage, and 1 patient developed rigors. At 90-day follow-up, 1 additional patient had died with a patent stent, and 3 patients had occluded biliary stents.
Cohort study.
Endobiliary RFA treatment appears to be safe. Randomized studies with prolonged follow-up are warranted.
在预期寿命超过 3 个月的无法切除的恶性胆管梗阻患者中,使用自膨式金属支架(SEMS)是确保持续胆道引流的标准技术。多达 50%的 SEMS 患者在 6 个月内会出现支架阻塞。尽管支架设计和组成的改变以及伴随的治疗都未能改善支架通畅性,但仍需要安全延长支架通畅性的替代技术。
证明腔内双极射频消融(RFA)在恶性胆道梗阻患者中的安全性,并报告这一新程序的 90 天胆道通畅率。
开放标签的试点研究。
单一的三级保健单位。
共 22 例无法切除的恶性胆管梗阻患者。
胆管内双极 RFA。
即刻和 30 天并发症以及 90 天支架通畅率。
共招募了 22 例患者(16 例为胰腺癌,6 例为胆管癌),招募时间为 2009 年 1 月至 2010 年 4 月。21 例患者成功部署了 RFA 导管。在所有成功部署 RFA 导管的病例中均进行了 SEMS 放置。1 例患者在 SEMS 放置后未能成功减压,在 90 天内死亡。所有其他患者在 30 天内保持支架通畅。1 例患者出现无症状性生化性胰腺炎,2 例患者需要经皮胆囊引流,1 例患者出现寒战。90 天随访时,另外 1 例患者死亡但支架通畅,3 例患者支架阻塞。
队列研究。
腔内 RFA 治疗似乎是安全的。需要进行随机研究并进行长期随访。